Contrary to popular opinion, hospitals that receive lower reimbursements from public programs often cut fees to private payers to adjust to the new normal. Medicaid expansion, in particular, has had a net positive effect because hospitals are faced with less uncompensated care.
Austin Frakt, PhD, a health economist with the Department of Veterans’ Affairs, has offered a commentary to dispel a widely held belief: that hospitals charge commercial insurers higher prices to make up for what they lose with Medicare and Medicaid patients. Frakt is a member of the editorial board of The American Journal of Managed Care®.
His essay appears on JAMA Forum, and comes as Republican members of Congress appear poised to use the budget resolution process to unravel the Affordable Care Act (ACA), possibly in the first weeks of President-elect Donald J. Trump’s administration. At this point, however, no viable replacement for the ACA is in sight, and Democrats have vowed to push back.
In this atmosphere, Frakt addresses the gulf between what the public believes and what the evidence shows. In part, he writes, it’s due to statements from payers themselves: he quotes the president of Blue Cross Blue Shield Vermont saying that payers must charge commercial customers higher rates to make up for the “shortfall created by government reimbursements.”
But Frakt asserts that “it’s been nearly 2 decades since any rigorous study has found evidence of substantial cost shifting.” In fact, he writes, the opposite is true—when Medicare and Medicaid cut payments, hospitals cut what they charge private insurers, which peg their reimbursements to the new normal. It makes sense that this happens, Frakt says, because hospitals want to be included in as many networks as possible.
Cost shifting only works if a hospital enjoys enough market power that it knows payers must include it in networks, even if its costs are not aligned with the public programs. He discusses recent work by Kathryn Wagner, PhD, MA, of Marquette on the effects of Medicaid expansion on hospital charges to private payers.
Frakt makes an important distinction. “Even if hospitals do not cost shift, they still cross subsidize. The additional revenue hospitals receive from higher payments from private insurers enable the provision of less profitable services. But this isn’t cost-shifting unless there is a causal, dynamic connection in which private prices rise because of public revenue shortfalls.”
Fears of cost shifting from Medicaid expansion are unfounded, in part because the trend has allowed hospitals to rely less on funds for uncompensated care. Multiple reports that compare the fortunes of safety net hospitals in expansion vs non-expansion states show that some urban hospitals are running in the black for the first time in decades, while many rural states, especially in the Deep South, have seen small hospitals close—uncompensated care funds have dwindled and patients who might have been eligible for Medicaid expansion show up at their doors without any coverage.
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen